Cardiac dysfunction in adipose triglyceride lipase deficiency: Treatment with a PPARα agonist

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 380-389

  Wolkart G ^a   Schrammel, A ^a   Dorffel K ^a   Haemmerle, G ^a   Zechner, R ^a   Mayer, Bernd Mayer ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

adipose triglyceride lipase deficiency; adrenergic stimulation; heart function; lipid accumulation; noradrenaline; PPAR ; PPAR

Indexed keywords

ADIPOSE TRIGLYCERIDE LIPASE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE DELETION; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; WALL STRESS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; FEMALE; HEART; HEART RATE; LIPASE; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; NOREPINEPHRINE; ORGAN SIZE; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; THIAZOLIDINEDIONES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 83755185494     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01490.x     Document Type: Article

References (50)

1. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, et al,. (2002). Peroxisome proliferator-activated receptor-γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105: 1240-1246. (Pubitemid 34225827)
2. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, et al,. (2002). Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22: 717-726. (Pubitemid 34517781)
3. Bishop SP, Altschuld RA, (1970). Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 218: 153-159.
4. Borradaile NM, Schaffer JE, (2005). Lipotoxicity in the heart. Curr Hypertens Rep 7: 412-417. (Pubitemid 43136936)
5. Brunner F, Andrew P, Wölkart G, Zechner R, Mayer B, (2001). Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 104: 3097-3102. (Pubitemid 34014064)
6. Campagna F, Nanni L, Quagliarini F, Pennisi E, Michailidis C, Pierelli F, et al,. (2008). Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochem Biophys Res Commun 377: 843-846.
7. Capaldo B, Napoli R, Di Marino L, Sacca L, (1992). Epinephrine directly antagonizes insulin-mediated activation of glucose uptake and inhibition of free fatty acid release in forearm tissues. Metabolism 41: 1146-1149.
8. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al,. (2001). A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822. (Pubitemid 32274034)
9. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, et al,. (2005). Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225-233. (Pubitemid 40209370)
10. Crabb DW, Pinaire J, Chou WY, Sissom S, Peters JM, Harris RA, et al,. (2001). Peroxisome proliferator-activated receptors (PPAR) and the mitochondrial aldehyde dehydrogenase (ALDH2) promoter in vitro and in vivo. Alcohol Clin Exp Res 25: 945-952. (Pubitemid 32656108)
11. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius Iii FC, et al,. (2007). Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethality. J Clin Invest 117: 812-822. (Pubitemid 46348540)
12. Feuvray D, Darmellah A, (2008). Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab 34 (Suppl. 1): 3-9. (Pubitemid 351389346)
13. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al,. (2002). The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130. (Pubitemid 34052548)
14. Fischer J, Lefàvre C, Morava E, Mussini JM, Laforêt P, Negre-Salvayre A, et al,. (2007). The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 39: 28-30. (Pubitemid 46026498)
15. Guellich A, Damy T, Lecarpentier Y, Conti M, Claes V, Samuel JL, et al,. (2007). Role of oxidative stress in cardiac dysfunction of PPARα -/- mice. Am J Physiol 293: H93-H102. (Pubitemid 47105063)
16. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, et al,. (2006). Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312: 734-737.
17. Hirano KI, Ikeda Y, Zaima N, Sakata Y, Matsumiya G, (2008). Triglyceride deposit cardiomyovasculopathy. N Engl J Med 359: 2396-2398.
18. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al,. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135.
19. Huang MT, Lee CF, Dobson GP, (1997). Epinephrine enhances glycogen turnover and depresses glucose uptake in vivo in rat heart. FASEB J 11: 973-980. (Pubitemid 27425899)
20. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, et al,. (2009). PPARγ in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119: 110-124.
21. Keller BJ, Bradford BU, Marsman DS, Cattley RC, Popp JA, Bojes HK, et al,. (1993). The nongenotoxic hepatocarcinogen Wy-14,643 is an uncoupler of oxidative phosphorylation in vivo. Toxicol Appl Pharmacol 119: 52-58. (Pubitemid 23109416)
22. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A, (2002). Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51: 1507-1514. (Pubitemid 34826618)
23. Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schäfer HL, et al,. (2009). The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin 30: 935-946.
24. Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G, et al,. (2006). Deletion of peroxisome proliferator-activated receptor-α induces an alteration of cardiac functions. Am J Physiol 291: H161-H166.
25. Marx N, Duez H, Fruchart JC, Staels B, (2004). Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94: 1168-1178. (Pubitemid 38656403)
26. Mirsky I, (1979). Elastic properties of the myocardium: a quantitative approach with physiological and clinical applications. In:, Berne R, Sperelakis N, Geiger S, (eds). Handbook of Physiology-The Cardiovascular System., Vol. I (The Heart). American Physiological Society: Bethesda, MD, pp. 497-531.
27. Molavi B, Chen J, Mehta JL, (2006). Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol 291: H687-H693. (Pubitemid 44175074)
28. Neely JR, Rovetto MJ, Oram JF, (1972). Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289-329.
29. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
30. Pinent M, Hackl H, Burkard TR, Prokesch A, Papak C, Scheideler M, et al,. (2008). Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice. Genomics 92: 26-32. (Pubitemid 351842628)
31. Robinson E, Grieve DJ, (2009). Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 122: 246-263.
32. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE, (2002). Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98: 33-39. (Pubitemid 35375651)
33. Schiffrin EL, (2005). Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol 288: H1037-H1043. (Pubitemid 40270004)
34. Sharifpanah F, Wartenberg M, Hannig M, Piper HM, Sauer H, (2008). Peroxisome proliferator-activated receptor-α agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. Stem Cells 26: 64-71.
35. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al,. (2004). Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18: 1692-1700. (Pubitemid 39463708)
36. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N, (1996). Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 45: 1168-1173. (Pubitemid 26300318)
37. Strömer H, Cittadini A, Szymanska G, Apstein CS, Morgan JP, (1997). Validation of different methods to compare cardiac function in isolated hearts of varying sizes. Am J Physiol 272: H501-H510.
38. Sutherland FJ, Shattock MJ, Baker KE, Hearse DJ, (2003). Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol 30: 867-878. (Pubitemid 37506155)
39. Touyz RM, Schiffrin EL, (2006). Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vasc Pharmacol 45: 19-28. (Pubitemid 43963482)
40. Veliotes DG, Woodiwiss AJ, Deftereos DA, Gray D, Osadchii O, Norton GR, (2005). Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation. Hypertension 45: 914-920. (Pubitemid 40628937)
41. Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, et al,. (2005). Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 313: 586-593. (Pubitemid 40604158)
42. Williamson JR, (1964). Metabolic effects of epinephrine in the isolated, perfused rat heart. I. Dissociation of the glycogenolytic from the metabolic stimulatory effect. J Biol Chem 239: 2721-2729.
43. Wittels B, Spann JF Jr, (1968). Defective lipid metabolism in the failing heart. J Clin Invest 47: 1787-1794.
44. Wölkart G, Strömer H, Brunner F, (2000). Calcium handling and role of endothelin-1 in monocrotaline right ventricular hypertrophy of the rat. J Mol Cell 32: 1995-2005.
45. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, et al,. (2003). Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426. (Pubitemid 36182219)
46. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K, (2001). Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104: 1670-1675. (Pubitemid 32947532)
47. Yeh CH, Chen TP, Lee CH, Wu YC, Lin YM, Lin PJ, (2006). Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor α but not γ activators. Shock 26: 262-270.
48. Zahradka P, (2007). Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARα) agonist Wy14,643. Cardiovasc Drug Rev 25: 99-122. (Pubitemid 47035425)
49. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, et al,. (2004). Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306: 1383-1386. (Pubitemid 39532517)
50. Zungu M, Young ME, Stanley WC, Essop MF, (2009). Chronic treatment with the peroxisome proliferator-activated receptor α agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function. Mol Cell Biochem 330: 55-62.